PURPOSE: To assess breast cancer (BC) risk after Hodgkin's lymphoma (HL) and compare characteristics, risk of second BC, and prognosis of patients with these BCs with patients with first primary BC. PATIENTS AND METHODS: We considered all 9,620 women with HL recorded in the Surveillance, Epidemiology and End Results dataset in 1973-2007. We calculated age-period standardized incidence ratios of BC. We compared patient, tumor, and treatment characteristics, risk of second BC, and prognosis between patients with BC after HL (n = 316) and patients with other BCs occurring during the same period (n = 450,413) using logistic regression and Cox models adjusted for confounders. RESULTS: HL patients had a 2.4-fold higher risk for developing BC (95% confidence interval [CI], 2.2-2.7) than the general population. Age at HL diagnosis and radiation therapy influenced this risk. Compared with first primary BCs, BCs after HL were diagnosed at a younger age, at an earlier stage, were less frequently hormone receptor positive, were located more frequently in external quadrants, and were less frequently treated using radiotherapy. These patients had a higher risk (adjusted hazard ratio [HR], 2.85; 95% CI, 1.79-4.53) for developing a second BC and had a higher BC mortality risk (adjusted HR, 1.36; 95% CI, 1.05-1.76). The higher mortality risk was only partly explained by the higher occurrence rate of a second BC. CONCLUSION: HL survivors have a higher risk for developing BC, their BCs are more aggressive, they have a higher risk for a second BC occurrence, and they have a poorer prognosis. Guidelines of care should be adapted to decrease the impact of BC in these high-risk patients.
PURPOSE: To assess breast cancer (BC) risk after Hodgkin's lymphoma (HL) and compare characteristics, risk of second BC, and prognosis of patients with these BCs with patients with first primary BC. PATIENTS AND METHODS: We considered all 9,620 women with HL recorded in the Surveillance, Epidemiology and End Results dataset in 1973-2007. We calculated age-period standardized incidence ratios of BC. We compared patient, tumor, and treatment characteristics, risk of second BC, and prognosis between patients with BC after HL (n = 316) and patients with other BCs occurring during the same period (n = 450,413) using logistic regression and Cox models adjusted for confounders. RESULTS: HL patients had a 2.4-fold higher risk for developing BC (95% confidence interval [CI], 2.2-2.7) than the general population. Age at HL diagnosis and radiation therapy influenced this risk. Compared with first primary BCs, BCs after HL were diagnosed at a younger age, at an earlier stage, were less frequently hormone receptor positive, were located more frequently in external quadrants, and were less frequently treated using radiotherapy. These patients had a higher risk (adjusted hazard ratio [HR], 2.85; 95% CI, 1.79-4.53) for developing a second BC and had a higher BC mortality risk (adjusted HR, 1.36; 95% CI, 1.05-1.76). The higher mortality risk was only partly explained by the higher occurrence rate of a second BC. CONCLUSION: HL survivors have a higher risk for developing BC, their BCs are more aggressive, they have a higher risk for a second BC occurrence, and they have a poorer prognosis. Guidelines of care should be adapted to decrease the impact of BC in these high-risk patients.
Authors: Mohamed A Alm El-Din; Kevin S Hughes; Dianne M Finkelstein; Keith A Betts; Torunn I Yock; Nancy J Tarbell; Alan C Aisenberg; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2008-06-04 Impact factor: 7.038
Authors: Marie L De Bruin; Judith Sparidans; Mars B van't Veer; Evert M Noordijk; Marieke W J Louwman; Josée M Zijlstra; Hendrik van den Berg; Nicola S Russell; Annegien Broeks; Margreet H A Baaijens; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Kathleen E Malone; Colin B Begg; Robert W Haile; Ake Borg; Patrick Concannon; Lina Tellhed; Shanyan Xue; Sharon Teraoka; Leslie Bernstein; Marinela Capanu; Anne S Reiner; Elyn R Riedel; Duncan C Thomas; Lene Mellemkjaer; Charles F Lynch; John D Boice; Hoda Anton-Culver; Jonine L Bernstein Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: G Sanna; K Lorizzo; N Rotmensz; V Bagnardi; S Cinieri; M Colleoni; F Nolè; A Goldhirsch Journal: Ann Oncol Date: 2006-11-06 Impact factor: 32.976
Authors: Ava Kwong; Steven L Hancock; Joan R Bloom; Sunita Pal; Robyn L Birdwell; Carol Mariscal; Debra M Ikeda Journal: Breast J Date: 2008 Jan-Feb Impact factor: 2.431
Authors: Mohamed A Alm El-Din; Kevin S Hughes; Rita A Raad; Saveli I Goldberg; Alan C Aisenberg; Andrzej Niemierko; Alphonse G Taghian Journal: Radiat Oncol Date: 2009-06-30 Impact factor: 3.481
Authors: Chaya S Moskowitz; Joanne F Chou; Joseph P Neglia; Ann H Partridge; Rebecca M Howell; Lisa R Diller; Danielle Novetsky Friedman; Dana Barnea; Lindsay M Morton; Lucie M Turcotte; Michael A Arnold; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger; Tara O Henderson Journal: J Clin Oncol Date: 2019-07-01 Impact factor: 44.544
Authors: Kevin T Lynch; William J Kane; Mark A Fleming; Raj P Desai; Shayna L Showalter; Craig L Slingluff; Daniel E Levin; Traci L Hedrick Journal: J Surg Oncol Date: 2021-03-31 Impact factor: 2.885